Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database
The current study supports concerns about the risk of OAEs when breast cancer patients use CDK4/6 inhibitors. Clinicians should raise awareness, conduct multidisciplinary assessments/management, and remind patients to pay attention to clinical symptoms. The potential differences among CDK4/6 inhibitors deserve further investigation.
Authors
- Minmin Yu (ORCID: https://orcid.org/0000-0003-4442-7586)
- Guangxi Shi
- Jingwei Li (ORCID: https://orcid.org/0000-0002-9949-9934)
- Mengdi Zhang (ORCID: https://orcid.org/0000-0001-5752-9464)
- Dongqing Pu
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fphar.2025.1668446
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China